Form CDC 57.210 CDC 57.210 Healthcare Worker Prophylaxis/Treatment

Facility ID#:		Med Admin#:
Healthcare Worker Demographics
*HCW ID#:
*HCW Name, Last:                First:                Middle:
*Gender:  F      M      Other         *Date of Birth:        /        /
*Work Location:	*Occupation:                       Clinical Specialty:
Information about the Antiviral Medication
Infectious agent: Influenza                                *For season:____________________                                                                       (specify years)
Assurance of Confidentiality:  The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.  An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN:  PRA (0920-0666). CDC 57.210 (Front), v6.4

 

Information about the Antiviral Medication (cont.)
Adverse reactions to antiviral medication #1: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #2: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #3: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #4: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
CDC 57.210 (Back), v6.4

 

Information about the Antiviral Medication (cont.)
Adverse reactions to antiviral medication #5: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #6: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #7: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #8: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis	Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
CDC 57.210 (Back), v6.4

 

Information about the Antiviral Medication (cont.)
Adverse reactions to antiviral medication #9: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis		Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Adverse reactions to antiviral medication #10: (check all that apply)
Acute respiratory failure Anaphylactic reaction Arrhythmia Behavior disturbances Bronchospasm Cardiac arrest Cardiac failure Coma Convulsions; seizure Delirium, delusions, stupor Erythema multiforme	Hemorrhagic colitis Hepatitis Hypotension; orthostatic hypotension Leukopenia; neutropenia Life threatening overdose Liver function test elevation Mydriasis (in patients with untreated angle closure glaucoma Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction Oropharyngeal edema   Psychosis		Pulmonary edema Serious skin rash Suicide or self-harm attempt Swelling of face or tongue Syncope Tachycardia Toxic epidermal necrolysis/Stevens    Johnson Syndrome Urinary retention Other ______________
Custom Fields
Label ________________________   ___/___/___ ________________________   ___________ ________________________   ___________ ________________________   ___________ ________________________   ___________ ________________________   ___________ ________________________   ___________		Label   ________________________   ___/___/___   ________________________   ___________   ________________________   ___________   ________________________   ___________   ________________________   ___________   ________________________   ___________   ________________________   ___________
Comments
CDC 57.210 (Back), v6.4

 

File Type	application/vnd.ms-powerpoint
File Title	Slide 1
Author	CDC
Last Modified By	ano3
File Modified	2010-08-04
File Created	2004-07-27

---

© 2024 OMB.report | Privacy Policy

---